We serve Chemical Name:Ubiquinone-1 CAS:727-81-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Ubiquinone-1
CAS.NO:727-81-1
Synonyms:Ubiquinone-5;Coenzyme Q1;2,3-dimethoxy-5-methyl-6-(3-methylbut-2-enyl)cyclohexa-2,5-diene-1,4-dione;Ubiquinone Q5;MFCD00274412;Coenzyme Q;Ubiquinone 1;CoQ1;Coenzyme Q5;Coenzymes Q;Ubiquinone Q1
Molecular Formula:C14H18O4
Molecular Weight:250.29000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:389.1ºC at 760 mmHg
Density:1.1g/cm3
Index of Refraction:1.504
PSA:52.60000
Exact Mass:250.12100
LogP:2.31540
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like Ubiquinone-5 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ubiquinone Q1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Coenzyme Q5 Use and application,Coenzyme Q1 technical grade,usp/ep/jp grade.
Related News: A strategic CDMO partner who can uphold a strong product manufacturing approach can positively influence timeline, quality, and costs of bringing the drug to market. (2,6-diphenyl-pyridin-3-ylmethyl)-diethyl-amine manufacturers For Franco Stevanato, tapping public markets will give the company the freedom to keep innovating as it enters the next chapter of its 70-plus-year history. N’-(5-acetyl-1,4-dimethyl-6-phenyl-1,6-dihydropyrimidin-2-yl)-3-methoxybenzohydrazide suppliers According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug. methyl 3-[dimethylamino(octadecanoyl)amino]propanoate vendor & factory The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.,According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug.
